Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
Open Access
- 26 November 2021
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 11 (11) , 1-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasmsBritish Journal of Haematology, 2021
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyThe Lancet Oncology, 2021
- Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institutionJournal of Hematology & Oncology, 2021
- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinibLeukemia, 2021
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsBlood, 2020
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyThe Lancet Haematology, 2020
- COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA surveyLeukemia, 2020
- Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortalityLeukemia, 2020
- Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumoniaThe Lancet Rheumatology, 2020
- A Modified Poisson Regression Approach to Prospective Studies with Binary DataAmerican Journal of Epidemiology, 2004